Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia

BACKGROUND: Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in western countries. Standard treatments include mono‐ or polychemotherapies, usually combined with monoclonal antibodies such as rituximab or alemtuzumab. However, the impa...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cochrane Database Syst Rev
Main Authors: Bauer, Kathrin, Rancea, Michaela, Roloff, Verena, Elter, Thomas, Hallek, Michael, Engert, Andreas, Skoetz, Nicole
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Ltd 2012
Fag:
Medicine General & Introductory Medical Sciences
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485963/
https://ncbi.nlm.nih.gov/pubmed/23152253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD008079.pub2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker